

Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX

GILEAD FUND AT A GLANCE

Manager: Dr. Finny Kuruvilla

Fund Objective: Seeks to provide long-term capital appreciation.

About the Fund: A diversified mutual fund representing our “best ideas” for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

Benchmarks: S&P 500 Total Return Index, Russell Midcap Growth Index

Morningstar Category: US Fund Mid-Cap Growth

Lipper Category: Mid-Cap Growth

Net Assets: \$3.14 billion

Inception Date: July 8, 2008

REVIEW

The Eventide Gilead Fund (Class N) posted a total return of 41.62% for the second quarter of 2020, compared with the S&P 500 Total Return Index of 20.54% and the Russell Midcap Growth Index of 30.26%. The Fund (Class N) posted a total return of 16.63% for the 12 months ending 6/30/2020 compared to the S&P 500 Total Return Index of 7.51% and the Russell Midcap Growth Index of 11.91%. The reasons for the Gilead Fund’s quarterly outperformance were overweights in high-growth software and e-commerce companies that rebounded as markets recovered from Covid fears.

CONTRIBUTORS

In the second quarter of 2020, the largest positive contributors to performance were Wayfair Inc, The Trade Desk Inc, Twilio Inc, CrowdStrike Holdings Inc, and Ascendis Pharma A/S. Wayfair saw significant improvement in their business growth and profitability due to COVID-19 as customers flocked to e-commerce to buy furniture to maintain social distancing while many of their competitors were affected negatively. The Trade Desk continues to come back with the market optimistic about the company’s best-in-class omnichannel advertising platform, especially Connected TV. Twilio has been the beneficiary of significant digital transformation in communications as enterprises and small/medium-sized businesses alike accelerate creation of digital customer experiences post-COVID. CrowdStrike continues to execute at a very high level on both revenues and profitability as enterprises look to adopt best in class endpoint cybersecurity solutions on the face of more sophisticated attack vectors. Shares of Ascendis Pharma ADRs performed well during the quarter as more investors learned about the potential of their pipeline candidates.

Top Five Contributors ¹					Q2 2020
Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
Wayfair Inc	W	Information Tech	3.04%	3.93%	269.78%
The Trade Desk Inc	TTD	Information Tech	3.28%	2.82%	110.62%
Twilio Inc	TWLO	Information Tech	2.39%	2.30%	145.19%
CrowdStrike Holdings Inc	CRWD	Information Tech	2.89%	1.96%	80.12%
Ascendis Pharma A/S	ASND	Healthcare	5.75%	1.91%	31.34%

DETRACTORS

In the second quarter of 2020, the largest negative detractors to performance were three different iShares put options, Varonis Systems Inc, and Trane Technologies. The three iShares puts were placed to hedge against tail risks, but lost value as software companies did well during the quarter. Varonis struggled during the pandemic quarter as customers slowed down purchasing decisions to get clarity on pipelines. Trane shares underperformed due to concerns about its nonresidential businesses.

Top Five Detractors ¹					Q2 2020
Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
iShares ETF Put	IGV Put	Information Tech	0.03%	-0.05%	-13.36%
iShares ETF Put	IGV Put	Information Tech	0.01%	-0.08%	-92.36%
Varonis Systems Inc	VRNS	Information Tech	0.10%	-0.12%	-2.83%
Trane Technologies	TT	Industrials	0.29%	-0.15%	-12.77%
iShares ETF Put	IGV Put	Information Tech	0.02%	-0.15%	-95.53%

MACRO COMMENTARY AND OUTLOOK

Because of Covid-19, the world of investing was gloomy and fearful as we began this quarter. But in the second quarter, three phenomena brought cheer to the market: 1) Covid-19 cases stabilized 2) the prospect of medical therapeutics grew brighter 3) the federal government passed an exceptionally large stimulus package. The convergence of these three forces in a short period of time caused equities to sharply rally. In addition, in the creative destruction that Covid-19 wrought, many industries have suffered greatly (e.g. cruise, airline, restaurant,

Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX

hospitality, oil and gas), while others have been beneficiaries (e.g. cloud computing, online commerce, telemedicine, biotechnology). As Satya Nadella, CEO of Microsoft (not a portfolio holding), said, "We have seen two years' worth of digital transformation in two months." In the last quarter's macro commentary, we urged investors to stay the course or add to equities because of the intense fear that had pummeled stocks in the first quarter. Now our enthusiasm has tempered. Stock valuations look full on a historic basis. However, compared to bonds, equities still look inexpensive. This we believe to be one of the key questions facing the market. If 10-year yields remain low, equity multiples can remain high. If the 10-year Treasury yield rallies, then equities look vulnerable. While there are good arguments on both sides, uncertainty on bond yields we believe merits caution on a conviction that equity valuations remain high. While we see a few pockets of value, we believe that a more prudent outlook is reasonable.

Trailing Returns ³							30 June 2020
Eventide Gilead Fund	YTD	1-year	3-Year ⁴	5-Year ⁴	10-Year ⁴	Since Inception ⁴	Inception Date ⁴
Class N	14.91%	16.63%	19.62%	12.21%	18.51%	15.60%	7/8/2008
Class A without load	14.89%	16.58%	19.56%	12.15%	18.46%	17.91%	10/28/2009
Class A with 5.75% load ⁵	8.29%	9.87%	17.23%	10.82%	17.75%	17.26%	10/28/2009
Class C	14.45%	15.71%	18.67%	11.31%	17.56%	17.02%	10/28/2009
Class I	15.00%	16.85%	19.86%	12.43%	18.74%	16.70%	2/2/2010
Benchmarks							
S&P 500 Total Return Index ⁶	-3.08%	7.51%	10.73%	10.73%	13.99%	10.02%	7/8/2008
Russell Midcap Growth Index ⁶	4.16%	11.91%	14.76%	11.60%	15.09%	11.18%	7/8/2008

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

Eventide Gilead Fund total annual fund operating expenses: Class A: 1.44%; Class C: 2.19%; Class I: 1.19%; Class N: 1.39%.

1. Source: Bloomberg PORT Attribution Report. Allocation percentages are subject to change at any time, and should not be considered investment advice.
2. The total return percentage listed is impacted by the Fund's transactions and transacted price levels of the holding during the quarter.
3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
4. Performance figures for periods greater than 1 year are annualized.
5. In the case of investments at or above the \$1 million breakpoint (where you do not pay an initial sales charge), a 1.00% contingent deferred sales charge ("CDSC") may be assessed on shares redeemed within eighteen months of purchase. The CDSC for these Class A shares is based on the NAV at the time of purchase. The holding period for the CDSC begins on the day you buy your shares. Some intermediaries may waive or discount the CDSC under certain circumstances.
6. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment.

The opinions expressed herein are those of the Fund's portfolio management team as of 6/30/2020 and are subject to change. There is no guarantee that such views are correct or that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.